Eli Lilly and Company announced that Melissa Seymour, MBA will join the company as executive vice president of Global Quality and member of the company’s Executive Committee, effective July 22, 2024. Seymour currently serves as the chief quality officer for…
Roche announced that its Elecsys pTau217 assay received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This blood test, which is being developed in collaboration with Eli Lilly and Company, will be used to help identify the…
Akouos, a wholly owned subsidiary of Eli Lilly and Company, announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated pharmacologic within 30 days of AK-OTOF administration in the first participant, an individual with a decade-plus history…
Organon, a global healthcare company with a focus on women’s health, announced an agreement with Eli Lilly and Company (Lilly) to become the sole distributor and promoter for the migraine medicines Emgality® (galcanezumab) and RAYVOW™(lasmiditan) in Europe. Emgality, a humanized…
FDA approved Eli Lilly and Company’s Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a…
Eli Lilly and Company announced today that the U.S. FDA has approved Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults.…
Eli Lilly and Company announced today that mirikizumab (an investigational interleukin-23p19 antagonist) met the co-primary and all major secondary endpoints compared to placebo in VIVID-1, a Phase 3 study evaluating the safety and efficacy of mirikizumab for the treatment of…